// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

PHASE 1 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN ß, IN PATIENTS WITH ADVANCED SOLID TUMORS, WITH A PHASE 2 EXPANSION IN RECURRENT GLIOBLASTOMA MULTIFORME

Stefan Symeonides - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

ST101

A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION

Scott Plotkin - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Dyslipidemia

N/A

EVALUATING DRUG DISTRIBUTION IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) TREATED WITH CONVECTION ENHANCED DRUG DELIVERY

Elwira Szychot - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse intrinsic pontine glioma

Sodium valproate

YB-1 AS A BIOMARKER FOR DRUG RESISTANCE AND TUMOUR PROGRESSION IN MEDULLOBLASTOMA

Louisa Taylor - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mismatch repair deficiency

Vincristine

TUMOR CELL IDO ENHANCES IMMUNE SUPPRESSION AND DECREASES SURVIVAL INDEPENDENT OF TRYPTOPHAN METABOLISM IN GLIOBLASTOMA

Lijie Zhai - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

tryptophan

A MULTI-DISCIPLINARY REVIEW OF NEWLY DIAGNOSED HIGH GRADE GLIOMA REFERRALS TO THERAPIES, AND IMPLEMENTATION OF A SCREENING TOOL TO IMPROVE ACCESS TO THERAPIES AT THE ROYAL MARSDEN HOSPITAL (RMH)

Joanne Jethwa - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High-Grade Gliomas

N/A

OLIGOSARCOMA, IDH-MUTANT IS A DISTINCT AGGRESSIVE TYPE

Abigail K Suwala - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Regain

INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED

Sybren Maas - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Meningiomas

N/A

RAPID-CNS2: RAPID COMPREHENSIVE ADAPTIVE NANOPORE-SEQUENCING OF CNS TUMORS, A PROOF OF CONCEPT STUDY

Areeba Patel - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cerebral metastases

N/A

INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT

Emilie Le Rhun - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Leptomeningeal Metastasis

N/A

PREDICTION OF GLIOBLASTOMA CELLULAR INFILTRATION AND RECURRENCE USING MACHINE LEARNING AND MULTI-PARAMETRIC MRI ANALYSIS: RESULTS FROM THE MULTI-INSTITUTIONAL RESPOND CONSORTIUM

Hamed Akbari - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

PROPOSED ORIGINS AND PATHWAYS OF DIFFUSE GLIOMAS REVEALED BY LESION COVARIANCE NETWORKS

Ayan Mandal - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Low-grade gliomas

N/A

RADIOMIC ANALYSIS FOR NON-INVASIVE IN VIVO PROGNOSTIC STRATIFICATION OF DE NOVO GLIOBLASTOMA PATIENTS: A MULTI-INSTITUTIONAL EVALUATION FOR GENERALIZABILITY IN THE RESPOND CONSORTIUM

Hamed Akbari - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

UNMET NEEDS AND WISH FOR SUPPORT OF FAMILY CAREGIVERS OF PRIMARY BRAIN TUMOUR PATIENTS

Lucy Pointon - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cerebral metastases

N/A

ION CHANNELS AS A THERAPEUTIC TARGET IN PAEDIATRIC HIGH-GRADE GLIOMAS

Michaela Griffin - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Glioblastoma

N/A

EFFICACY OF SOLUBLE PANOBINOSTAT (MTX110) IN PRECLINICAL MODELS OF ADULT GLIOBLASTOMA

Greg Palmer - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Panobinostat

TRIAL WORKING GROUPS TO EXPEDITE PRECLINICAL TRANSLATION FOR PAEDIATRIC BRAIN TUMOURS

Ruman Rahman - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cerebral metastases

N/A

HEALTH-RELATED QUALITY OF LIFE (HRQOL) AMONG PEDIATRIC PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMA (PN) IN THE UNITED STATES: PERSPECTIVES OF THE PATIENTS AND CAREGIVERS

Xiaoqin Yang - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Neurofibromatosis type 1

selumetinib

HEALTH-RELATED QUALITY OF LIFE IN LOW-GRADE GLIOMA SURVIVORS 26 YEARS AFTER DIAGNOSIS

Florien Boele - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Low-grade gliomas

N/A

LONG-TERM IMPACT OF ADULT GLIOMA ON HEALTH-RELATED QUALITY OF LIFE: A SYSTEMATIC REVIEW

Se Maria Frances - Society for Neuro-Oncology (SNO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

N/A

Copyright © 2026. QuantiNova All rights reserved